These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32844378)

  • 1. A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis.
    Schmidt WA; Dasgupta B; Luqmani R; Unizony SH; Blockmans D; Lai Z; Kurrasch RH; Lazic I; Brown K; Rao R
    Rheumatol Ther; 2020 Dec; 7(4):793-810. PubMed ID: 32844378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Venhoff N; Schmidt WA; Bergner R; Rech J; Unger L; Tony HP; Finzel S; Andreica I; Kofler DM; Weiner SM; Lamprecht P; Schulze-Koops H; App C; Pournara E; Mendelson MH; Sieder C; Maricos M; Thiel J
    Lancet Rheumatol; 2023 Jun; 5(6):e341-e350. PubMed ID: 38251601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.
    Venhoff N; Schmidt WA; Lamprecht P; Tony HP; App C; Sieder C; Legeler C; Jentzsch C; Thiel J
    Trials; 2021 Aug; 22(1):543. PubMed ID: 34404463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Cid MC; Unizony SH; Blockmans D; Brouwer E; Dagna L; Dasgupta B; Hellmich B; Molloy E; Salvarani C; Trapnell BC; Warrington KJ; Wicks I; Samant M; Zhou T; Pupim L; Paolini JF;
    Ann Rheum Dis; 2022 May; 81(5):653-661. PubMed ID: 35264321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.
    Schmidt WA; Dasgupta B; Sloane J; Giannelou A; Xu Y; Unizony SH; Mackie SL; Gonzalez-Gay MA; Spiera R; Warrington KJ; Villiger PM; Nivens MC; Akinlade B; Lin Y; Buttgereit F; Stone JH
    Arthritis Res Ther; 2023 Oct; 25(1):199. PubMed ID: 37840134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.
    Takeuchi T; Thorne C; Karpouzas G; Sheng S; Xu W; Rao R; Fei K; Hsu B; Tak PP
    Ann Rheum Dis; 2017 Dec; 76(12):2001-2008. PubMed ID: 28855173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of Tocilizumab in Giant-Cell Arteritis.
    Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N
    N Engl J Med; 2017 Jul; 377(4):317-328. PubMed ID: 28745999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).
    Tanaka Y; Takeuchi T; Harigai M; Yamanaka H; Nakano T; Akagi K; Ukyo Y; Hsu B
    Mod Rheumatol; 2019 Mar; 29(2):306-313. PubMed ID: 29532734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.
    Seror R; Baron G; Hachulla E; Debandt M; Larroche C; Puéchal X; Maurier F; de Wazieres B; Quéméneur T; Ravaud P; Mariette X
    Ann Rheum Dis; 2014 Dec; 73(12):2074-81. PubMed ID: 23897775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
    Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schulze-Koops H; Schett G; Spiera R; Unizony SH; Collinson N
    Arthritis Rheumatol; 2019 Aug; 71(8):1329-1338. PubMed ID: 30835950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
    Stone JH; Han J; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Unizony SH; Bao M;
    Lancet Rheumatol; 2021 May; 3(5):e328-e336. PubMed ID: 38279390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
    Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
    Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
    Taylor PC; Schiff MH; Wang Q; Jiang Y; Zhuang Y; Kurrasch R; Daga S; Rao R; Tak PP; Hsu B
    Ann Rheum Dis; 2018 May; 77(5):658-666. PubMed ID: 29483080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study.
    Takeuchi T; Tanaka Y; Yamanaka H; Harigai M; Nakano T; Akagi K; Ukyo Y; Hsu B
    Mod Rheumatol; 2018 Nov; 28(6):941-949. PubMed ID: 29336187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.
    Rovin BH; van Vollenhoven RF; Aranow C; Wagner C; Gordon R; Zhuang Y; Belkowski S; Hsu B
    Arthritis Rheumatol; 2016 Sep; 68(9):2174-83. PubMed ID: 27110697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study.
    Thorne C; Takeuchi T; Karpouzas GA; Sheng S; Kurrasch R; Fei K; Hsu B
    RMD Open; 2018; 4(2):e000731. PubMed ID: 30564449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of the tocilizumab in giant cell arteritis trial.
    Unizony SH; Dasgupta B; Fisheleva E; Rowell L; Schett G; Spiera R; Zwerina J; Harari O; Stone JH
    Int J Rheumatol; 2013; 2013():912562. PubMed ID: 23653652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
    Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.